In Hopewell, N.Y., a historical marker commemorates the 1814 death of Timothy Ryan — the second known fatality in North America from an insect sting, according to the plaque. Two hundred years later, we still see at least 50 deaths a year from stings.
Allergy & Asthma Network is now recruiting participants for Women Breathe Free, an asthma education program made especially for women — with the goal of helping women everywhere gain better control over their asthma, and their lives.
The program will help women develop asthma management skills to handle situations and symptoms that can lead to an asthma flare, such as stress, menstrual cycles, not taking medications, or exposure to triggers such as cleaning chemicals, pollen, mold or dust mites.
HOW IT WORKS?
Women Breathe Free offers four telephone counseling sessions conducted by a nurse educator during times that fit into your schedule. Upon joining the program, you will receive a workbook and review it with the nurse educator to learn what causes your asthma to worsen, what helps keep it under control and how to track your symptoms.
The program also aims to assist in strengthening communication between you and your health care provider to get the most out of your asthma treatment. The goal is to help you control your asthma so you can live YOUR healthiest life possible.
Women Breathe Free is open to women 18 years or older with diagnosed asthma. It is FREE and confidential – no personal information will be collected.
WANT TO JOIN?
For more information, call Allergy & Asthma Network at 800.878.4403 or email Marcela Gieminiani, at firstname.lastname@example.org.
When Beth’s eczema flares, she gets itchy red blotches on the backs of her arms – and sometimes from nose to cheek. “Just the left side,” she says. “Never on the right. This month, I’ve got a dime-size spot on my hand that won’t go away.”
Spread the news: Two pieces of critical legislation affecting schoolchildren with life-threatening allergies in New York State are on Gov. Andrew Cuomo’s desk awaiting signature. You can help complete passage of these bills by contacting the governor and encouraging him to sign!
M. Razi Rafeeq, MD, a board-certified allergist and Anaphylaxis Community Expert (ACE) from Toledo, Ohio, recently testified before the Ohio House Education Committee in support of HB 296, legislation that allows schools to stock auto-injectable epinephrine to treat life-threatening allergic reactions, or anaphylaxis.
VIENNA, VA, JUNE 2, 2014 – You’re back at work after a relaxing vacation, and by noon your head aches and the nagging cough returns. Is it stress? A virus? Or could you be allergic to something in the office?
– Wherever Your Destination
When Diane, a 22-year-old graduate student at the University of Maryland, packed for a three-week study abroad course in Morocco last winter, she never thought she would need an epinephrine auto-injector.
Diane figured she had long outgrown her food allergies. She hadn’t had an allergic reaction to peanut since 2000 – when she was 9 years old.
Allergy immunotherapy gradually builds a person’s tolerance to specific allergens by exposing the patient to ever-increasing doses over a period of time – eventually reducing or eliminating symptoms. Read the rest of this entry »
U.S. Rep. Carol Shea-Porter (D-NH) envisions a day when people say, “There once was a disease called asthma.” She sees a time in the not-too-distant future when parents tell kids, “People actually used to die from eating peanut butter.”
What will it take to reach that day? A renewed emphasis on medical research, patient education, high-quality and ethical care, federal and community programs – and most of all, a commitment to patient safety. Read the rest of this entry »
Allergy and asthma medications are at the forefront of the U.S. Food and Drug Administration (FDA) agenda this year as the agency considers moving more drugs from prescription to over-the-counter (OTC) status.
Two medications recently considered were Nasacort®, the corticosteroid nasal spray approved for OTC use in late 2013, and Primatene HFA, an OTC asthma bronchodilator still under consideration at this time.